WO2005037245A3 - A multiple route medication for the treatment of rhinitis and asthma - Google Patents

A multiple route medication for the treatment of rhinitis and asthma Download PDF

Info

Publication number
WO2005037245A3
WO2005037245A3 PCT/DK2004/000718 DK2004000718W WO2005037245A3 WO 2005037245 A3 WO2005037245 A3 WO 2005037245A3 DK 2004000718 W DK2004000718 W DK 2004000718W WO 2005037245 A3 WO2005037245 A3 WO 2005037245A3
Authority
WO
WIPO (PCT)
Prior art keywords
active composition
asthma
route
rhinitis
combination
Prior art date
Application number
PCT/DK2004/000718
Other languages
French (fr)
Other versions
WO2005037245A2 (en
Inventor
Troels Keldmann
Erik Keldmann
Original Assignee
Direct Haler As
Troels Keldmann
Erik Keldmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Haler As, Troels Keldmann, Erik Keldmann filed Critical Direct Haler As
Priority to EP04762937A priority Critical patent/EP1680084A2/en
Publication of WO2005037245A2 publication Critical patent/WO2005037245A2/en
Publication of WO2005037245A3 publication Critical patent/WO2005037245A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A multiple route medication for the prophylactic and/or therapeutic treatment of rhinitis and asthma based on the concept of “one airway-one disease”. A first preset amount of an active composition for the oral route is given together with preset amount of a second active composition for the nasal route and optionally also with a third preset amount of a third active composition for the pulmonary route. The first active composition can include an antihistamine, such as loratidine, desloratidine, fexofenadine, HCI, ebastine, mizolastine, mequitazine or ceterizine, an anti-leukotriene, such as montelukast, zafirlukast or pranlukast or a combination of an- antihistamine and a anti-leukotriene. The second active composition can include a coticosteroid such as budesonide, fluticasone propionate, beclomethasone, momethasone, flunisolide, triamcinolone acetonide or ciclesonide. The third active composition can include a corticosteroid of the same type or a combination of such corticosteroid with a β2-agonist, such as salmeterol and formoterol. The invention provides a fixed daily dosing of a combination of specific drugs to be taken in sequence by specific delivery route administration within a specific time frame in order to obtain relief from rhinitis and asthma symptoms and prevention or postponing the escalation of asthma from intermittent through mild, moderate to severe persistent asthma. Preferably the fixed daily doses are to be given once a day or as subdivided doses to be given twice a day.
PCT/DK2004/000718 2003-10-21 2004-10-19 A multiple route medication for the treatment of rhinitis and asthma WO2005037245A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04762937A EP1680084A2 (en) 2003-10-21 2004-10-19 A multiple route medication for the treatment of rhinitis and asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301548 2003-10-21
DKPA200301548 2003-10-21

Publications (2)

Publication Number Publication Date
WO2005037245A2 WO2005037245A2 (en) 2005-04-28
WO2005037245A3 true WO2005037245A3 (en) 2005-08-11

Family

ID=34442834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000718 WO2005037245A2 (en) 2003-10-21 2004-10-19 A multiple route medication for the treatment of rhinitis and asthma

Country Status (2)

Country Link
EP (1) EP1680084A2 (en)
WO (1) WO2005037245A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2916142A1 (en) * 2007-05-15 2008-11-21 Pierre Fabre Medicament Sa PHARMACEUTICAL FORM COMPRISING (10 - [(3S) -1-AZABICYCLO [2.2.2] OCT-3-YLMETHYL] -10H-PHENOTHIAZINE PRESENTING IN AN APPROPRIATE FORM FOR ADMINISTRATION OF A DAILY DOSE UNDER BETWEEN 1 AND 3 MG
US20220265583A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020393A1 (en) * 1994-01-27 1995-08-03 Schering Corporation Use of mometasone furoate for treating airway passage and lung diseases
WO1997001337A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
WO1997028797A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composion
US5830490A (en) * 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
US20030050290A1 (en) * 1999-03-03 2003-03-13 Hassan Ian Francis Combination of formoterol and mometasone furoate for asthma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020393A1 (en) * 1994-01-27 1995-08-03 Schering Corporation Use of mometasone furoate for treating airway passage and lung diseases
WO1997001337A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
WO1997028797A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composion
US5830490A (en) * 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
US20030050290A1 (en) * 1999-03-03 2003-03-13 Hassan Ian Francis Combination of formoterol and mometasone furoate for asthma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUHLBRIGGE ANNE L ET AL: "The effect of treatment of allergic rhinitis on asthma morbidity, including emergency department visits.", CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY. UNITED STATES FEB 2003, vol. 3, no. 1, February 2003 (2003-02-01), pages 29 - 32, XP008026754, ISSN: 1528-4050 *
LEE L M ET AL: "Pre and post treatment mucociliary function in allergic rhinitis in three different treatment modalities.", THE MEDICAL JOURNAL OF MALAYSIA. MAR 2003, vol. 58, no. 1, March 2003 (2003-03-01), pages 17 - 20, XP008049073, ISSN: 0300-5283 *
LIPWORTH B J ET AL: "Allergic inflammation in the unified airway: Start with the nose", THORAX 2000 UNITED KINGDOM, vol. 55, no. 10, 2000, pages 878 - 881, XP002267709, ISSN: 0040-6376 *

Also Published As

Publication number Publication date
WO2005037245A2 (en) 2005-04-28
EP1680084A2 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
Greiner et al. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy
Buhl Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma
US7867508B1 (en) Treatment of upper respiratory conditions
WO2011141929A2 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2002083113A3 (en) Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
EA201290375A1 (en) COMBINATION THERAPY COPD
EP1392321A4 (en) Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
NZ600789A (en) Aerosol formulation for copd
MX340924B (en) Pharmaceutical compositions.
Albertson et al. Pharmacotherapy of critical asthma syndrome: current and emerging therapies
US20200281896A1 (en) Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
Galant et al. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
NZ592861A (en) Pharmaceutical aerosol composition
WO2005037245A3 (en) A multiple route medication for the treatment of rhinitis and asthma
AR078494A1 (en) PHARMACEUTICAL FORMULATIONS IN FORMOTEROL AEROSOL AND BECLOMETASONE DIPROPIONATE
Van Cauwenberge et al. Glucocorticosteroids in allergic inflammation: clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media
Nathan Intranasal steroids in the treatment of allergy-induced rhinorrhea
Giavina-Bianchi et al. Fluticasone furoate nasal spray in the treatment of allergic rhinitis
Ahmadiafshar et al. Efficacy and safety of inhaled and intranasal corticosteroids
Masekela et al. Asthma treatment in children: A pragmatic approach
Neighbour et al. Montelukast in the treatment of asthma and allergic rhinitis
US20140294737A1 (en) Treatment of rhinitis
Hur Treatment of allergic rhinitis
Leflein et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma
Whittaker Nasal sprays: a short review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004762937

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004762937

Country of ref document: EP